FY2024 Earnings Estimate for BioSyent Issued By Bloom Burton

BioSyent Inc. (CVE:RX) – Investment analysts at Bloom Burton boosted their FY2024 earnings per share (EPS) estimates for BioSyent in a report released on Thursday, November 21st. Bloom Burton analyst D. Martin now anticipates that the company will post earnings per share of $0.63 for the year, up from their prior forecast of $0.59. The consensus estimate for BioSyent’s current full-year earnings is $0.69 per share. Bloom Burton also issued estimates for BioSyent’s FY2025 earnings at $0.80 EPS and FY2026 earnings at $0.91 EPS.

BioSyent Stock Down 1.5 %

RX opened at C$11.52 on Monday. The firm has a market capitalization of C$133.52 million, a P/E ratio of 19.20 and a beta of 0.93. BioSyent has a one year low of C$8.24 and a one year high of C$11.74. The company has a fifty day moving average price of C$11.06 and a 200-day moving average price of C$10.29. The company has a debt-to-equity ratio of 3.19, a current ratio of 6.13 and a quick ratio of 6.91.

BioSyent (CVE:RX) last issued its quarterly earnings data on Monday, August 26th. The company reported C$0.13 EPS for the quarter, meeting the consensus estimate of C$0.13. The company had revenue of C$8.95 million during the quarter, compared to analysts’ expectations of C$8.80 million. BioSyent had a net margin of 21.14% and a return on equity of 20.88%.

Insider Activity at BioSyent

In related news, insider FAX Capital Corp. sold 230,800 shares of the firm’s stock in a transaction that occurred on Friday, November 22nd. The shares were sold at an average price of C$11.12, for a total value of C$2,566,496.00. Also, Director Seyed Ahmad Ashrafi sold 2,320 shares of BioSyent stock in a transaction that occurred on Friday, September 20th. The shares were sold at an average price of C$10.95, for a total transaction of C$25,404.00. Over the last quarter, insiders sold 234,357 shares of company stock valued at $2,605,854. Company insiders own 33.65% of the company’s stock.

BioSyent Company Profile

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.